Drugs / Prostaglandin E2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02801227 | Sep 2016 → Sep 2017 | preterm premature rupture of the membranes | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT00545194 Comparator | Jan 2002 → Oct 2004 | cervix disorder | French National Institute of Health and Medical Research | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04743297 Comparator | Mar 2021 → Jan 2023 | preterm premature rupture of the membranes | University Medical Centre Maribor | Unknown | No outcome recorded |
| — | NCT03471858 Comparator | Aug 2019 → Aug 2022 | pregnancy disorder | Ministry of Health, Singapore | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prostaglandin E2 | “Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix.” NCT03471858 ↗ |
| Known as | Propess | “Propess - Prostaglandin E2 Vaginal Delivery System. Slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.” NCT04743297 ↗ |
| Route | Other | “Intravaginal gel” NCT00545194 ↗ |